文献速递中毒与环境急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

口服水飞蓟素对急性肝毒性蘑菇中毒患者的疗效:一项毒物中心数据分析

Effect of oral silymarin in patients with acute hepatotoxic mushroom poisoning: an analysis of poison center data.
PubMed 文献 · Clin Toxicol (Phila) · 2025-12-11
一句话结论回顾性毒物中心数据显示,口服水飞蓟素未降低急性肝毒性蘑菇中毒患者的院内死亡率、急性肝衰竭发生率或住院时长,但可能与急性肾损伤发生率降低相关。

该回顾性观察研究纳入泰国拉玛提博迪毒物中心2016年1月至2024年5月报告的255例15岁及以上、食用野生蘑菇后出现迟发胃肠症状或转氨酶升高的患者。33例(12.9%)接受口服水飞蓟素治疗。总体院内死亡率为5.1%,水飞蓟素组死亡率为3.0%,低于非水飞蓟素组的5.4%,但校正混杂因素后水飞蓟素与死亡率降低无关。水飞蓟素组急性肝衰竭发生率和住院时长未降低,但急性肾损伤发生率降低(校正风险差=-13.9%[95%CI:-23.6至-4.1%];P=0.005),且无药物不良反应报告。

要点

  • 在255例急性肝毒性蘑菇中毒患者中,校正混杂因素后口服水飞蓟素与院内死亡率降低无关联。
  • 水飞蓟素组急性肾损伤发生率降低,校正风险差为-13.9%(95%CI:-23.6至-4.1%;P=0.005)。
  • 水飞蓟素组急性肝衰竭发生率和住院时长均未降低。
  • 研究期间未观察到水飞蓟素相关药物不良反应。
  • 该结论来自单中心回顾性毒物中心数据,作者认为需进一步研究评估治疗获益与成本效益。

适用人群与场景

  • 纳入标准:2016年1月至2024年5月报告至泰国拉玛提博迪毒物中心、年龄15岁及以上、食用野生蘑菇、且满足以下任一条件:胃肠症状在摄入后5小时或更晚出现,或天冬氨酸氨基转移酶或丙氨酸氨基转移酶活性升高且无可识别病因的患者。

诊断标准与关键阈值

  • 纳入标准中迟发胃肠症状的界值为摄入后5小时或更晚出现。
  • 纳入标准中转氨酶升高定义为天冬氨酸氨基转移酶或丙氨酸氨基转移酶活性升高且无可识别病因。

研究设计与关键结果

  • 研究类型:回顾性观察研究,单中心毒物中心数据,纳入255例患者,总体院内死亡率为5.1%。
  • 33例(12.9%)接受口服水飞蓟素治疗;水飞蓟素组死亡率为3.0%,非水飞蓟素组死亡率为5.4%。
  • 校正潜在混杂因素后,水飞蓟素与死亡率降低无关联。
  • 水飞蓟素组急性肝衰竭发生率和住院时长未降低。
  • 水飞蓟素组急性肾损伤发生率降低,校正风险差=-13.9%(95%CI:-23.6至-4.1%;P=0.005)。
  • 未报告药物不良反应。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 局限:原文报告为回顾性数据,来自单中心毒物中心;需进一步研究评估治疗获益与成本效益。

对床旁实践的改变

  • 对于急性肝毒性蘑菇中毒患者,口服水飞蓟素未显示降低院内死亡率、急性肝衰竭发生率或住院时长,作者认为其可能降低急性肾损伤发生率。
  • 作者认为需进一步研究评估口服水飞蓟素的治疗获益与成本效益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Intravenous silibinin may reduce mortality in patients with hepatotoxic mushroom poisoning, but it is unavailable in some countries. This study aimed to evaluate the effectiveness of oral silymarin as an alternative treatment for decreasing mortality.

METHODS: This retrospective observational study included patients reported to Ramathibodi Poison Center, Thailand, from January 2016 to May 2024. Eligibility criteria were patients aged 15 years or older who ingested foraged mushrooms, with either onset of gastrointestinal symptoms at 5 h or more or elevated aspartate aminotransferase or alanine aminotransferase activities without identifiable causes. The primary outcome was in-hospital mortality. The secondary outcomes were acute liver failure, acute kidney injury, hospital length of stay, and adverse drug events. Multivariable risk regression and regression of means were used to estimate the adjusted risk difference while controlling for confounding variables.

RESULTS: A total of 255 patients were included, with an overall mortality of 5.1%. Thirty-three patients (12.9%) received silymarin. The mortality rate in the silymarin group was 3.0%, which is lower than the 5.4% mortality rate in the non-silymarin group. After adjusting for potential confounders, silymarin was not associated with a decrease in mortality. The incidence of acute liver failure and hospital length of stay were not reduced in the silymarin group, though the incidence of acute kidney injury was reduced (adjusted risk difference = -13.9% [95% CI: -23.6 to -4.1%]; P = 0.005). There were no adverse drug reactions.

DISCUSSION: Our findings were derived from retrospective data at a single poison center; further studies are warranted to evaluate the treatment benefits and cost-effectiveness.

CONCLUSIONS: We were unable to demonstrate a reduction in mortality, acute liver failure, or hospital length of stay associated with oral silymarin use. However, it appeared to decrease the incidence of acute kidney injury.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Tangsuwanaruk T, Tansuwannarat P, Tongpoo A, et al. Effect of oral silymarin in patients with acute hepatotoxic mushroom poisoning: an analysis of poison center data. Clin Toxicol (Phila). 2025. PMID: 41378447. doi:10.1080/15563650.2025.2586098

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。